Stock Analysis

Orion Oyj Third Quarter 2024 Earnings: Beats Expectations

HLSE:ORNBV
Source: Shutterstock

Orion Oyj (HEL:ORNBV) Third Quarter 2024 Results

Key Financial Results

  • Revenue: €471.3m (up 56% from 3Q 2023).
  • Net income: €160.8m (up 162% from 3Q 2023).
  • Profit margin: 34% (up from 20% in 3Q 2023). The increase in margin was driven by higher revenue.
  • EPS: €1.14 (up from €0.44 in 3Q 2023).
earnings-and-revenue-growth
HLSE:ORNBV Earnings and Revenue Growth October 30th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Orion Oyj Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 8.2%.

Looking ahead, revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Finland.

The company's shares are down 6.8% from a week ago.

Risk Analysis

Be aware that Orion Oyj is showing 2 warning signs in our investment analysis that you should know about...

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About HLSE:ORNBV

Orion Oyj

Develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally.

Outstanding track record with excellent balance sheet and pays a dividend.